Skip to main content
. 2024 Mar 13;11(4):ofae144. doi: 10.1093/ofid/ofae144

Figure 1.

Figure 1.

Concurrent bivalent COVID-19 mRNA and influenza boosters induce more durable IgG1 responses to spike. A, Cohort analyzed in this study. Participants were divided into those who received a bivalent mRNA COVID-19 booster and flu vaccine on the same day (concurrently) or different days. Blood was drawn at peak immunogenicity (2–4 weeks) and 6 months after the bivalent COVID-19 mRNA booster. B, IgG1 antibody responses to the predominantly circulating COVID-19 spike variant at the time of this study XBB.1.5 (top) as well as the ancestral (Wu-1) and Omicron BA.5 (bottom) spikes that represent the vaccine immunogens. C, IgM antibody responses were quantified similarly to panel B and serve as a control to assess de novo antibody affinity maturation. White circle, mean; line, median; box, IQR; error bars, 95% CI. Fold differences and P values are shown. *P < .05. ns, not significant. Mann-Whitney U test/Wilcoxon rank sum test.